Maravai Lifesciences Holdings (MRVI) Non-Current Debt (2020 - 2026)

Maravai Lifesciences Holdings' Non-Current Debt history runs 7 years deep, the most recent figure standing at $241.0 million for Q1 2026.

• On a quarterly basis, Non-Current Debt fell 16.75% year-over-year to $241.0 million in Q1 2026; TTM through Mar 2026 was $241.0 million, a 16.75% decrease from a year earlier, with the FY2025 full-year figure at $286.3 million, down 3.24% from the prior year.
• Non-Current Debt eased to $241.0 million in Q1 2026 per MRVI's latest filing, from $286.3 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $711.2 million in Q2 2022 and bottomed at $241.0 million in Q1 2026.
• The 5-year median for Non-Current Debt is $517.9 million (2024), against an average of $468.0 million.
• Across the five-year window, Non-Current Debt jumped 35.32% in 2022 and tumbled 44.34% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $522.0 million in 2022, then grew by 0.41% to $524.1 million in 2023, then slumped by 43.54% to $295.9 million in 2024, then decreased by 3.24% to $286.3 million in 2025, then fell by 15.83% to $241.0 million in 2026.
• Per Business Quant, the three latest MRVI Non-Current Debt figures stand at $241.0 million (Q1 2026), $286.3 million (Q4 2025), and $287.4 million (Q3 2025).